Haemonetics Corp HAE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
-
Haemonetics Updates Financial Reporting Segments
-
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
-
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
-
Haemonetics to Present at Bank of America 2026 Healthcare Conference
-
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Trading Information
- Previous Close Price
- $75.00
- Day Range
- $74.67–76.58
- 52-Week Range
- $47.32–87.32
- Bid/Ask
- $57.40 / $88.88
- Shares Outstanding
- 45.45M
- Market Cap
- $3.46B
- Volume/Avg
- 456,265 / 885,823
Key Statistics
- Price/Earnings (Normalized)
- 15.07
- Price/Sales
- 2.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 5.05%
Company Profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,009
- Website
- https://www.haemonetics.com
Competitors
Valuation
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Price/Earnings (Normalized) | 15.07 | 14.99 |
Price/Book Value | 4.26 | 2.12 |
Price/Sales | 2.66 | 2.90 |
Price/Cash Flow | 11.58 | 12.07 |
Price/Earnings
HAE
MDT
Financial Strength
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Quick Ratio | 1.64 | 1.36 |
Current Ratio | 2.95 | 2.13 |
Interest Coverage | 5.46 | 9.58 |
Quick Ratio
HAE
MDT
Profitability
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Return on Assets (Normalized) | 9.59% | 7.76% |
Return on Equity (Normalized) | 27.55% | 14.65% |
Return on Invested Capital (Normalized) | 12.35% | 9.93% |
Return on Assets
HAE
MDT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|F&!z?% | LOCK|>cbJB | $164B | |||
| Stryker Corp
SYK
| LOCK|N$#&v%?! | LOCK|Ysq | $126B | |||
| Medtronic PLC
MDT
| LOCK|#>JF?^n | LOCK|T<#j# | $107B | |||
| Boston Scientific Corp
BSX
| LOCK|Y$mwk@ | LOCK|@KlG | $67B | |||
| Edwards Lifesciences Corp
EW
| LOCK|DnnLH@H | LOCK|jj?gb | $53B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|&nz?lr^ | LOCK|@j | $29B | |||
| DexCom Inc
DXCM
| LOCK|?wnKH!m | LOCK|Fr>< | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|^J | LOCK|rw | $27B | |||
| Steris PLC
STE
| LOCK|PV<&CF | LOCK|>!N^? | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|&Vt!gk?& | LOCK|rm | $18B |
United States